# L_2008059EN.01001901.xml

| 4.3.2008 | EN | Official Journal of the European Union | L 59/19 |
| --- | --- | --- | --- |

4.3.2008

EN

Official Journal of the European Union

L 59/19

---

COMMISSION DECISION

of 21 February 2008

on additional guarantees in intra-Community trade of pigs relating to Aujeszky’s disease and criteria to provide information on this disease

(notified under document number C(2008) 669)

(Codified version)

(Text with EEA relevance)

(2008/185/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Directive 64/432/EEC of 26 June 1964 on animal health problems affecting intra-Community trade in bovine animals and swine (1), and in particular Article 8, Article 9(2) and Article 10(2) thereof,

Whereas:

| (1) | Commission Decision 2001/618/EC of 23 July 2001 on additional guarantees in intra-Community trade of pigs relating to Aujeszky’s disease, criteria to provide information on this disease and repealing Decisions 93/24/EEC and 93/244/EEC (2) has been substantially amended several times (3). In the interests of clarity and rationality the said Decision should be codified. |
| --- | --- |

(1)

Commission Decision 2001/618/EC of 23 July 2001 on additional guarantees in intra-Community trade of pigs relating to Aujeszky’s disease, criteria to provide information on this disease and repealing Decisions 93/24/EEC and 93/244/EEC (2) has been substantially amended several times (3). In the interests of clarity and rationality the said Decision should be codified.

| (2) | The International Office of Epizootic Diseases (OIE) is the international organisation designated under the Agreement on the Application of Sanitary and Phytosanitary Measures in application of GATT 1994 which is responsible for the establishment of international animal health rules for trade in animals and animal products. These rules are published in the International Animal Health Code. |
| --- | --- |

(2)

The International Office of Epizootic Diseases (OIE) is the international organisation designated under the Agreement on the Application of Sanitary and Phytosanitary Measures in application of GATT 1994 which is responsible for the establishment of international animal health rules for trade in animals and animal products. These rules are published in the International Animal Health Code.

| (3) | The chapter of the International Animal Health Code on Aujeszky’s disease has been substantially amended. |
| --- | --- |

(3)

The chapter of the International Animal Health Code on Aujeszky’s disease has been substantially amended.

| (4) | It is appropriate to modify the additional guarantees required in intra-Community trade of pigs in relation to Aujeszky’s disease in order to ensure their consistency with the international rules on this disease and better control in the Community. |
| --- | --- |

(4)

It is appropriate to modify the additional guarantees required in intra-Community trade of pigs in relation to Aujeszky’s disease in order to ensure their consistency with the international rules on this disease and better control in the Community.

| (5) | Criteria must be established on the information to be provided by the Member States on Aujeszky’s disease, in accordance with Article 8 of Directive 64/432/EEC. |
| --- | --- |

(5)

Criteria must be established on the information to be provided by the Member States on Aujeszky’s disease, in accordance with Article 8 of Directive 64/432/EEC.

| (6) | The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health, |
| --- | --- |

(6)

The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,

HAS ADOPTED THIS DECISION:

Article 1

The dispatching of pigs intended for breeding or production destined for the Member States or regions free of Aujeszky’s disease listed in Annex I and coming from any other Member State or region not listed in that Annex is authorised subject to the following conditions:

| 1. | Aujeszky’s disease must be compulsorily notifiable in the Member State of origin; |
| --- | --- |

1.

Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

| 2. | a plan for the control and eradication of Aujeszky’s disease, fulfilling the criteria laid down in Article 9(1) of Directive 64/432/EEC, must be in place in the Member State or regions of origin under the supervision of the competent authority. Appropriate measures on pig transport and movements must be in place according to this plan for preventing a spread of disease between holdings of a different status; |
| --- | --- |

2.

a plan for the control and eradication of Aujeszky’s disease, fulfilling the criteria laid down in Article 9(1) of Directive 64/432/EEC, must be in place in the Member State or regions of origin under the supervision of the competent authority. Appropriate measures on pig transport and movements must be in place according to this plan for preventing a spread of disease between holdings of a different status;

| 3. | with regard to the holding of origin of the pigs:






  (a) | no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding in question; |
| --- | --- | --- |

3.

with regard to the holding of origin of the pigs:

(a)

no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding in question;

| (b) | no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holdings located in an area of 5 km surrounding the holding of origin of the pigs; however, this provision shall not apply if, in these latter holdings, disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority and in accordance with the eradication plan referred to in point (2), and these measures have effectively prevented any spread of disease to the holding in question; |
| --- | --- |

(b)

no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holdings located in an area of 5 km surrounding the holding of origin of the pigs; however, this provision shall not apply if, in these latter holdings, disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority and in accordance with the eradication plan referred to in point (2), and these measures have effectively prevented any spread of disease to the holding in question;

| (c) | vaccination against Aujeszky’s disease has not been carried out for at least 12 months; |
| --- | --- |

(c)

vaccination against Aujeszky’s disease has not been carried out for at least 12 months;

| (d) | the pigs have been subjected on at least two occasions at an interval of at least four months to a serological survey for the presence of ADV-gE or ADV-gB or ADV-gD antibody or to the whole Aujeszky’s disease virus. This survey must have shown the absence of Aujeszky’s disease and that vaccinated pigs have been free from gE antibodies; |
| --- | --- |

(d)

the pigs have been subjected on at least two occasions at an interval of at least four months to a serological survey for the presence of ADV-gE or ADV-gB or ADV-gD antibody or to the whole Aujeszky’s disease virus. This survey must have shown the absence of Aujeszky’s disease and that vaccinated pigs have been free from gE antibodies;

| (e) | no pigs have been introduced from holdings of a lower animal health status as regards Aujeszky’s disease in the previous 12 months, unless they have been tested for Aujeszky’s disease with negative results; |
| --- | --- |

(e)

no pigs have been introduced from holdings of a lower animal health status as regards Aujeszky’s disease in the previous 12 months, unless they have been tested for Aujeszky’s disease with negative results;

| 4. | the pigs to be moved:






  (a) | have not been vaccinated; |
| --- | --- | --- |

4.

the pigs to be moved:

(a)

have not been vaccinated;

| (b) | have been kept isolated in accommodation approved by the competent authority, during the 30 days prior to movement, and in such a way that any risk of spreading Aujeszky’s disease to these pigs is prevented; |
| --- | --- |

(b)

have been kept isolated in accommodation approved by the competent authority, during the 30 days prior to movement, and in such a way that any risk of spreading Aujeszky’s disease to these pigs is prevented;

| (c) | must have lived in the holding of origin or in a holding of an equivalent status since birth, and have remained in the holding of origin for at least:






  (i) | 30 days, in the case of pigs intended for production; |
| --- | --- | --- |

(c)

must have lived in the holding of origin or in a holding of an equivalent status since birth, and have remained in the holding of origin for at least:

(i)

30 days, in the case of pigs intended for production;

| (ii) | 90 days, in the case of pigs intended for breeding; |
| --- | --- |

(ii)

90 days, in the case of pigs intended for breeding;

| (d) | have been subjected with negative results to at least two serological tests for ADV-gB or ADV-gD or the whole Aujeszky’s disease virus, at a distance of at least 30 days between each test. However, in case of pigs less than four months old, the serological test for ADV-gE may also be used. Sampling for the last test must be performed within 15 days prior to shipment. The number of pigs tested in the isolation unit must be sufficient to detect:






  (i) | 2 % seroprevalence with 95 % confidence in the isolation unit in case of pigs intended for production; |
| --- | --- | --- |

(d)

have been subjected with negative results to at least two serological tests for ADV-gB or ADV-gD or the whole Aujeszky’s disease virus, at a distance of at least 30 days between each test. However, in case of pigs less than four months old, the serological test for ADV-gE may also be used. Sampling for the last test must be performed within 15 days prior to shipment. The number of pigs tested in the isolation unit must be sufficient to detect:

(i)

2 % seroprevalence with 95 % confidence in the isolation unit in case of pigs intended for production;

| (ii) | 0,1 % seroprevalence with 95 % confidence in the isolation unit in case of pigs intended for breeding. |
| --- | --- |

(ii)

0,1 % seroprevalence with 95 % confidence in the isolation unit in case of pigs intended for breeding.

However, the first of the two tests shall not be necessary if:

| (i) | in the framework of the plan referred to in point (2), a serological survey has been carried out in the holding of origin between 45 and 170 days prior to shipment, demonstrating the absence of Aujeszky’s disease antibodies and that vaccinated pigs have been free from gE antibodies; |
| --- | --- |

(i)

in the framework of the plan referred to in point (2), a serological survey has been carried out in the holding of origin between 45 and 170 days prior to shipment, demonstrating the absence of Aujeszky’s disease antibodies and that vaccinated pigs have been free from gE antibodies;

| (ii) | the pigs to be moved have lived in the holding of origin since birth; |
| --- | --- |

(ii)

the pigs to be moved have lived in the holding of origin since birth;

| (iii) | no pigs have moved on to the holding of origin while the pigs to be moved have been kept in isolation. |
| --- | --- |

(iii)

no pigs have moved on to the holding of origin while the pigs to be moved have been kept in isolation.

Article 2

The dispatching of pigs intended for slaughter destined for the Member States or regions free of Aujeszky’s disease listed in Annex I and coming from any other Member State or region not listed in that Annex, is authorised subject to the following conditions:

| 1. | Aujeszky’s disease must be compulsorily notifiable in the Member State of origin; |
| --- | --- |

1.

Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

| 2. | a plan for the control and eradication of Aujeszky’s disease is in place in the Member State or regions of origin of the pigs, fulfilling the criteria laid down in Article 1(2); |
| --- | --- |

2.

a plan for the control and eradication of Aujeszky’s disease is in place in the Member State or regions of origin of the pigs, fulfilling the criteria laid down in Article 1(2);

| 3. | all the pigs in question must be transported directly to the slaughterhouse of destination and either:






  (a) | they come from a holding which fulfils the conditions laid down in Article 1(3); or |
| --- | --- | --- |

3.

all the pigs in question must be transported directly to the slaughterhouse of destination and either:

(a)

they come from a holding which fulfils the conditions laid down in Article 1(3); or

| (b) | they have been vaccinated against Aujeszky’s disease at least 15 days prior to their shipment and come from a holding of origin where:






  (i) | in the framework of the plan referred to in point (2), Aujeszky’s disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority for the previous 12 months; |
| --- | --- | --- |

(b)

they have been vaccinated against Aujeszky’s disease at least 15 days prior to their shipment and come from a holding of origin where:

(i)

in the framework of the plan referred to in point (2), Aujeszky’s disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority for the previous 12 months;

| (ii) | they had remained for at least 30 days before dispatch and where no clinical or pathological evidence of this disease has been detected at the moment of completion of the health certificate referred to in Article 7; or |
| --- | --- |

(ii)

they had remained for at least 30 days before dispatch and where no clinical or pathological evidence of this disease has been detected at the moment of completion of the health certificate referred to in Article 7; or

| (c) | they have not been vaccinated and they proceed from a holding where:






  (i) | in the framework of the plan referred to in point 2, Aujeszky’s disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority in the previous 12 months and no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous six months; |
| --- | --- | --- |

(c)

they have not been vaccinated and they proceed from a holding where:

(i)

in the framework of the plan referred to in point 2, Aujeszky’s disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority in the previous 12 months and no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous six months;

| (ii) | vaccination against Aujeszky’s disease and introduction of vaccinated pigs have been forbidden by the competent authority, since the holding is in the process of reaching the highest status as regards Aujeszky’s disease in accordance to the plan referred to in point (2); |
| --- | --- |

(ii)

vaccination against Aujeszky’s disease and introduction of vaccinated pigs have been forbidden by the competent authority, since the holding is in the process of reaching the highest status as regards Aujeszky’s disease in accordance to the plan referred to in point (2);

| (iii) | they have lived for at least 90 days before dispatch. |
| --- | --- |

(iii)

they have lived for at least 90 days before dispatch.

Article 3

Pigs intended for breeding destined for the Member States or regions listed in Annex II, where approved Aujeszky’s disease eradication programmes are in place, must either:

| 1. | come from Member States or regions listed in Annex I; or |
| --- | --- |

1.

come from Member States or regions listed in Annex I; or

| 2. | come from:






  (a) | Member States or regions listed in Annex II; and |
| --- | --- | --- |

2.

come from:

(a)

Member States or regions listed in Annex II; and

| (b) | a holding which fulfils the requirements of Article 1(3); or |
| --- | --- |

(b)

a holding which fulfils the requirements of Article 1(3); or

| 3. | fulfil the following conditions:






  (a) | Aujeszky’s disease must be compulsorily notifiable in the Member State of origin; |
| --- | --- | --- |

3.

fulfil the following conditions:

(a)

Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

| (b) | a plan for the control and eradication of Aujeszky’s disease is in place in the Member States or region of origin, which fulfils the criteria laid down in Article 1(2); |
| --- | --- |

(b)

a plan for the control and eradication of Aujeszky’s disease is in place in the Member States or region of origin, which fulfils the criteria laid down in Article 1(2);

| (c) | no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding of origin of the pigs in question; |
| --- | --- |

(c)

no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding of origin of the pigs in question;

| (d) | the pigs must have been isolated in accommodation approved by the competent authority for the 30 days immediately prior to movement and kept isolated in such a way that any risk of spreading of Aujeszky’s disease is prevented; |
| --- | --- |

(d)

the pigs must have been isolated in accommodation approved by the competent authority for the 30 days immediately prior to movement and kept isolated in such a way that any risk of spreading of Aujeszky’s disease is prevented;

| (e) | the pigs must have been subjected, with negative results, to a serological test for the presence of gE antibodies. Sampling for the last test must be performed within 15 days prior to shipment. The number of pigs tested must be sufficient to detect 2 % seroprevalence with 95 % confidence in these pigs; |
| --- | --- |

(e)

the pigs must have been subjected, with negative results, to a serological test for the presence of gE antibodies. Sampling for the last test must be performed within 15 days prior to shipment. The number of pigs tested must be sufficient to detect 2 % seroprevalence with 95 % confidence in these pigs;

| (f) | the pigs must have lived in the holding of origin or in a holding of an equivalent status since birth, and have remained in the holding of origin for at least 90 days. |
| --- | --- |

(f)

the pigs must have lived in the holding of origin or in a holding of an equivalent status since birth, and have remained in the holding of origin for at least 90 days.

Article 4

Pigs intended for production destined for the Member States or regions listed in Annex II, where approved Aujeszky’s disease eradication programmes are in place, must either:

| 1. | come from Member States or regions listed in Annex I; or |
| --- | --- |

1.

come from Member States or regions listed in Annex I; or

| 2. | come from:






  (a) | Member States or regions listed in Annex II; and |
| --- | --- | --- |

2.

come from:

(a)

Member States or regions listed in Annex II; and

| (b) | a holding which fulfils the requirements of Article 1(3); or |
| --- | --- |

(b)

a holding which fulfils the requirements of Article 1(3); or

| 3. | fulfil the following conditions:






  (a) | Aujeszky’s disease must be compulsorily notifiable in the Member State of origin; |
| --- | --- | --- |

3.

fulfil the following conditions:

(a)

Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

| (b) | a plan for the control and eradication of Aujeszky’s disease is in place in the Member States or region of origin, which fulfils the criteria laid down in Article 1 point (2); |
| --- | --- |

(b)

a plan for the control and eradication of Aujeszky’s disease is in place in the Member States or region of origin, which fulfils the criteria laid down in Article 1 point (2);

| (c) | no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding of origin of the pigs in question; |
| --- | --- |

(c)

no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding of origin of the pigs in question;

| (d) | a serological survey for Aujeszky’s disease, demonstrating its absence and that vaccinated pigs have been free from gE antibodies, has been carried out in the holding of origin and between 45 and 170 days prior to shipment; |
| --- | --- |

(d)

a serological survey for Aujeszky’s disease, demonstrating its absence and that vaccinated pigs have been free from gE antibodies, has been carried out in the holding of origin and between 45 and 170 days prior to shipment;

| (e) | the pigs must either have lived in the holding of origin since birth or have remained in such holdings for at least 30 days after introduction from a holding of an equivalent status, where a serological survey equivalent to the one referred to in point (d) has been carried out. |
| --- | --- |

(e)

the pigs must either have lived in the holding of origin since birth or have remained in such holdings for at least 30 days after introduction from a holding of an equivalent status, where a serological survey equivalent to the one referred to in point (d) has been carried out.

Article 5

The serological tests carried out to monitor or detect Aujeszky’s disease in pigs in accordance with this Decision must meet the standards laid down in Annex III.

Article 6

Without prejudice to Article 10(3) of Directive 64/432/EEC, information on the occurrence of Aujeszky’s disease, including details of the monitoring and eradication programmes in operation in the Member States listed in Annex II and in the other Member States or regions not listed in that Annex where monitoring and eradication programmes are in place, must be provided at least annually by each Member State in accordance with the uniform criteria laid down in Annex IV.

Article 7

1.   Without prejudice to the provisions laid down in Community legislation concerning health certificates, before the completion, for animals of the porcine species destined for Member States or regions listed in Annex I or II, of section C of the health certificate required by Directive 64/432/EEC, the official veterinarian shall ascertain:

| (a) | the status of the holding and of the Member State or region of origin of the pigs in question as regards Aujeszky’s disease; |
| --- | --- |

(a)

the status of the holding and of the Member State or region of origin of the pigs in question as regards Aujeszky’s disease;

| (b) | in case the pigs are not originating from a Member State or a region free of the disease, the status of the holding and of the Member State or regions of destination for the pigs in question as regards Aujeszky’s disease; |
| --- | --- |

(b)

in case the pigs are not originating from a Member State or a region free of the disease, the status of the holding and of the Member State or regions of destination for the pigs in question as regards Aujeszky’s disease;

| (c) | the compliance of the pigs in question with the conditions laid down in this Decision. |
| --- | --- |

(c)

the compliance of the pigs in question with the conditions laid down in this Decision.

2.   For animals of the porcine species destined for Member States or regions listed in Annex I or II, the certification under paragraph 4 of Section C of the health certificate referred to in paragraph 1 shall be completed and supplemented as follows:

| (a) | in the first indent, after the word ‘disease’ the word ‘Aujeszky’ must be added; |
| --- | --- |

(a)

in the first indent, after the word ‘disease’ the word ‘Aujeszky’ must be added;

| (b) | in the second indent, reference shall be made to this Decision. In the same line, the number of the Article of this Decision, which is relevant for the pigs in question, shall be quoted between brackets. |
| --- | --- |

(b)

in the second indent, reference shall be made to this Decision. In the same line, the number of the Article of this Decision, which is relevant for the pigs in question, shall be quoted between brackets.

Article 8

Member States must ensure that when pigs destined for Member States or regions listed in Annex I or II are transported, they shall not come in contact with pigs of different or unknown status, as regards Aujeszky’s disease, during transport or transit.

Article 9

Decision 2001/618/EC is repealed.

References to the repealed Decision shall be construed as references to this Decision and shall be read in accordance with the correlation table in Annex VI.

Article 10

This Decision is addressed to the Member States.

Done at Brussels, 21 February 2008.

For the Commission

The President

José Manuel BARROSO

---

(1)  
  OJ 121, 29.7.1964, p. 1977/64. Directive as last amended by Commission Decision 2007/729/EC (OJ L 294, 13.11.2007, p. 26).

1

(2)  
  OJ L 215, 9.8.2001, p. 48. Decision as last amended by Decision 2007/729/EC.

2

(3)  See Annex V.

3

---

ANNEX I

Member States or regions thereof free of Aujeszky’s disease and where vaccination is prohibited

| ISO code | Member State | Regions |
| --- | --- | --- |
| CZ | Czech Republic | All regions |
| DK | Denmark | All regions |
| DE | Germany | All regions |
| FR | France | The departments of Ain, Aisne, Allier, Alpes-de-Haute-Provence, Alpes-Maritimes, Ardèche, Ardennes, Ariège, Aube, Aude, Aveyron, Bas-Rhin, Bouches-du-Rhône, Calvados, Cantal, Charente, Charente-Maritime, Cher, Corrèze, Côte-d’Or, Creuse, Deux-Sèvres, Dordogne, Doubs, Drôme, Essonne, Eure, Eure-et-Loir, Gard, Gers, Gironde, Hautes-Alpes, Hauts-de-Seine, Haute Garonne, Haute-Loire, Haute-Marne, Hautes-Pyrénées, Haut-Rhin, Haute-Saône, Haute-Savoie, Haute-Vienne, Hérault, Indre, Indre-et-Loire, Isère, Jura, Landes, Loire, Loire-Atlantique, Loir-et-Cher, Loiret, Lot, Lot-et-Garonne, Lozère, Maine-et-Loire, Manche, Marne, Mayenne, Meurthe-et-Moselle, Meuse, Moselle, Nièvre, Oise, Orne, Paris, Pas-de-Calais, Pyrénées-Atlantiques, Pyrénées-Orientales, Puy-de-Dôme, Réunion, Rhône, Sarthe, Saône-et-Loire, Savoie, Seine-et-Marne, Seine-Maritime, Seine-Saint-Denis, Somme, Tarn, Tarn-et-Garonne, Territoire de Belfort, Val-de-Marne, Val-d’Oise, Var, Vaucluse, Vendée, Vienne, Vosges, Yonne, Yvelines |
| CY | Cyprus | Whole territory |
| LU | Luxembourg | All regions |
| AT | Austria | Whole territory |
| SK | Slovakia | All regions |
| FI | Finland | All regions |
| SE | Sweden | All regions |
| UK | United Kingdom | All regions in England, Scotland and Wales |

ISO code

Member State

Regions

CZ

Czech Republic

All regions

DK

Denmark

All regions

DE

Germany

All regions

FR

France

The departments of Ain, Aisne, Allier, Alpes-de-Haute-Provence, Alpes-Maritimes, Ardèche, Ardennes, Ariège, Aube, Aude, Aveyron, Bas-Rhin, Bouches-du-Rhône, Calvados, Cantal, Charente, Charente-Maritime, Cher, Corrèze, Côte-d’Or, Creuse, Deux-Sèvres, Dordogne, Doubs, Drôme, Essonne, Eure, Eure-et-Loir, Gard, Gers, Gironde, Hautes-Alpes, Hauts-de-Seine, Haute Garonne, Haute-Loire, Haute-Marne, Hautes-Pyrénées, Haut-Rhin, Haute-Saône, Haute-Savoie, Haute-Vienne, Hérault, Indre, Indre-et-Loire, Isère, Jura, Landes, Loire, Loire-Atlantique, Loir-et-Cher, Loiret, Lot, Lot-et-Garonne, Lozère, Maine-et-Loire, Manche, Marne, Mayenne, Meurthe-et-Moselle, Meuse, Moselle, Nièvre, Oise, Orne, Paris, Pas-de-Calais, Pyrénées-Atlantiques, Pyrénées-Orientales, Puy-de-Dôme, Réunion, Rhône, Sarthe, Saône-et-Loire, Savoie, Seine-et-Marne, Seine-Maritime, Seine-Saint-Denis, Somme, Tarn, Tarn-et-Garonne, Territoire de Belfort, Val-de-Marne, Val-d’Oise, Var, Vaucluse, Vendée, Vienne, Vosges, Yonne, Yvelines

CY

Cyprus

Whole territory

LU

Luxembourg

All regions

AT

Austria

Whole territory

SK

Slovakia

All regions

FI

Finland

All regions

SE

Sweden

All regions

UK

United Kingdom

All regions in England, Scotland and Wales

---

ANNEX II

Member States or regions thereof where approved Aujeszky’s disease control programmes are in place

| ISO code | Member State | Regions |
| --- | --- | --- |
| BE | Belgium | Whole territory. |
| ES | Spain | The territory of the Autonomous Communities of Galicia, País Vasco, Asturias, Cantabria, Navarra, La Rioja.
  The territory of the provinces of León, Zamora, Palencia, Burgos, Valladolid and Ávila in the Autonomous Community of Castilla y León.
  The territory of the province of Las Palmas in the Canary Islands. |
| FR | France | The departments of Côtes-d’Armor, Finistère, Ille-et-Vilaine, Morbihan and Nord. |
| IT | Italy | The Province of Bolzano. |
| NL | Netherlands | Whole territory. |

ISO code

Member State

Regions

BE

Belgium

Whole territory.

ES

Spain

The territory of the Autonomous Communities of Galicia, País Vasco, Asturias, Cantabria, Navarra, La Rioja.

The territory of the provinces of León, Zamora, Palencia, Burgos, Valladolid and Ávila in the Autonomous Community of Castilla y León.

The territory of the province of Las Palmas in the Canary Islands.

FR

France

The departments of Côtes-d’Armor, Finistère, Ille-et-Vilaine, Morbihan and Nord.

IT

Italy

The Province of Bolzano.

NL

Netherlands

Whole territory.

---

ANNEX III

Standards for Aujeszky’s disease serological tests — Protocol for the enzyme linked immunosorbent assay (ELISA) for detecting antibodies to Aujeszky’s disease virus (whole virus), to glycoprotein B (ADV-gB), to glycoprotein D (ADV-gD) or to glycoprotein E (ADV-gE)

| 1. | The institutes listed in paragraph 2(d) shall evaluate Elisa ADV-gE tests and kits against the criteria in paragraph 2(a), (b) and (c). The competent authority in each Member State shall ensure that only Elisa ADV-gE kits that meet these standards shall be registered. The examinations listed in 2(a) and (b) must be carried out prior to approval of the test and the examination in 2(c), at least, must thereafter be carried out on each batch. |
| --- | --- |

1.

| 2. | Standardisation, sensitivity and specificity of the test.






  (a) | The sensitivity of the test must be of such a level that the following Community reference sera are scored positive:






  — | Community reference serum ADV 1 at 1:8 dilution, |
| --- | --- | --- | --- |

2.

(a)

The sensitivity of the test must be of such a level that the following Community reference sera are scored positive:

—

Community reference serum ADV 1 at 1:8 dilution,

| — | Community reference serum ADV-gE A, |
| --- | --- |

—

Community reference serum ADV-gE A,

| — | Community reference serum ADV-gE B, |
| --- | --- |

—

Community reference serum ADV-gE B,

| — | Community reference serum ADV-gE C, |
| --- | --- |

—

Community reference serum ADV-gE C,

| — | Community reference serum ADV-gE D, |
| --- | --- |

—

Community reference serum ADV-gE D,

| — | Community reference serum ADV-gE E, |
| --- | --- |

—

Community reference serum ADV-gE E,

| — | Community reference serum ADV-gE F. |
| --- | --- |

—

Community reference serum ADV-gE F.

| (b) | The specificity of the test must be of such a level that the following Community reference sera are scored negative:






  — | Community reference serum ADV-gE G, |
| --- | --- | --- |

(b)

The specificity of the test must be of such a level that the following Community reference sera are scored negative:

—

Community reference serum ADV-gE G,

| — | Community reference serum ADV-gE H, |
| --- | --- |

—

Community reference serum ADV-gE H,

| — | Community reference serum ADV-gE J, |
| --- | --- |

—

Community reference serum ADV-gE J,

| — | Community reference serum ADV-gE K, |
| --- | --- |

—

Community reference serum ADV-gE K,

| — | Community reference serum ADV-gE L, |
| --- | --- |

—

Community reference serum ADV-gE L,

| — | Community reference serum ADV-gE M, |
| --- | --- |

—

Community reference serum ADV-gE M,

| — | Community reference serum ADV-gE N, |
| --- | --- |

—

Community reference serum ADV-gE N,

| — | Community reference serum ADV-gE O, |
| --- | --- |

—

Community reference serum ADV-gE O,

| — | Community reference serum ADV-gE P, |
| --- | --- |

—

Community reference serum ADV-gE P,

| — | Community reference serum ADV-gE Q. |
| --- | --- |

—

Community reference serum ADV-gE Q.

| (c) | For batch control, Community reference serum ADV 1 must be scored positive at 1:8 dilution and one of the Community reference sera from ADV-gE G to ADV-gE Q, as listed in point (b), must be scored negative.
  For batch control of ADV-gB and ADV-gD kits, Community reference serum ADV 1 must be scored positive at the dilution of 1:2 and Community reference serum Q referred to in (b) should be scored negative. |
| --- | --- |

(c)

For batch control, Community reference serum ADV 1 must be scored positive at 1:8 dilution and one of the Community reference sera from ADV-gE G to ADV-gE Q, as listed in point (b), must be scored negative.

For batch control of ADV-gB and ADV-gD kits, Community reference serum ADV 1 must be scored positive at the dilution of 1:2 and Community reference serum Q referred to in (b) should be scored negative.

| (d) | The institutes listed below will, in addition, be responsible for checking the quality of the ELISA method in each Member State, and in particular for producing and standardising national reference sera according to the Community reference sera.






  AT | AGES: Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH — Institut für veterinärmedizinische Untersuchungen Mödling (Austrian Agency for Health and Consumer Protection — Institute for veterinary investigations Mödling) |
| --- | --- | --- |
| Robert Koch-Gasse 17 |
| A-2340 Mödling |
| Tel. +43 (0) 505 55-38112 |
| Fax +43 (0) 505 55-38108 |
| E-mail: vetmed.moedling@ages.at |

(d)

The institutes listed below will, in addition, be responsible for checking the quality of the ELISA method in each Member State, and in particular for producing and standardising national reference sera according to the Community reference sera.

AT

AGES: Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH — Institut für veterinärmedizinische Untersuchungen Mödling (Austrian Agency for Health and Consumer Protection — Institute for veterinary investigations Mödling)

Robert Koch-Gasse 17

A-2340 Mödling

Tel. +43 (0) 505 55-38112

Fax +43 (0) 505 55-38108

E-mail: vetmed.moedling@ages.at

BE

| CODA — CERVA — VAR |
| --- |
| Veterinary and Agrochemical Research Centre |
| Groeselenberg 99 |
| B-1180 Brussels |

CODA — CERVA — VAR

Veterinary and Agrochemical Research Centre

Groeselenberg 99

B-1180 Brussels

CY

| State Veterinary Laboratory |
| --- |
| Veterinary Services |
| 1417 Athalassa |
| Nicosia |

State Veterinary Laboratory

Veterinary Services

1417 Athalassa

Nicosia

CZ

—

DE

| Friedrich-Loeffler-Institut |
| --- |
| Bundesforschungsinstitut für Tiergesundheit |
| Standort Wusterhausen |
| Seestraße 55 |
| D-16868 Wusterhausen |
| Tel. + 49 33979 80-0 |
| Fax + 49 33979 80-200 |

Friedrich-Loeffler-Institut

Bundesforschungsinstitut für Tiergesundheit

Standort Wusterhausen

Seestraße 55

D-16868 Wusterhausen

Tel. + 49 33979 80-0

Fax + 49 33979 80-200

DK

| National Veterinary Institute, Technical University of Denmark |
| --- |
| Lindholm |
| DK-4771 Kalvehave |

National Veterinary Institute, Technical University of Denmark

Lindholm

DK-4771 Kalvehave

EE

| Veterinaar- ja Toidulaboratoorium |
| --- |
| Kreutzwaldi 30, 51006 Tartu, Estonia |
| Tel. + 372 7 386 100 |
| Faks: + 372 7 386 102 |
| E-mail: info@vetlab.ee |

Veterinaar- ja Toidulaboratoorium

Kreutzwaldi 30, 51006 Tartu, Estonia

Tel. + 372 7 386 100

Faks: + 372 7 386 102

E-mail: info@vetlab.ee

ES

| Laboratorio Central de Sanidad Animal de Algete |
| --- |
| Carretera de Algete, km 8 |
| Algete 28110 (Madrid) |
| Tel. +34 916 290 300 |
| Fax +34 916 290 598 |
| E-mail: lcv@mapya.es |

Laboratorio Central de Sanidad Animal de Algete

Carretera de Algete, km 8

Algete 28110 (Madrid)

Tel. +34 916 290 300

Fax +34 916 290 598

E-mail: lcv@mapya.es

FI

| Finnish Food Safety Authority |
| --- |
| Animal Diseases and Food Safety Research |
| Mustialankatu 3 |
| FI-00790 Helsinki, Finland |
| E-mail: info@evira.fi |
| Tel. +358 20 772 003 (exchange) |
| Fax +358 20 772 4350 |

Finnish Food Safety Authority

Animal Diseases and Food Safety Research

Mustialankatu 3

FI-00790 Helsinki, Finland

E-mail: info@evira.fi

Tel. +358 20 772 003 (exchange)

Fax +358 20 772 4350

FR

| Laboratoire d’études et de recherches avicoles, porcines et piscicoles |
| --- |
| AFSSA site de Ploufragan/Brest — |
| LERAPP |
| BP 53 |
| 22440 Ploufragan |

Laboratoire d’études et de recherches avicoles, porcines et piscicoles

AFSSA site de Ploufragan/Brest —

LERAPP

BP 53

22440 Ploufragan

UK

| Veterinary Laboratories Agency |
| --- |
| New Haw, Addlestone, Weybridge |
| Surrey KT15 3NB, UK |
| Tel. (44-1932) 341111 |
| Fax (44-1932) 347046 |

Veterinary Laboratories Agency

New Haw, Addlestone, Weybridge

Surrey KT15 3NB, UK

Tel. (44-1932) 341111

Fax (44-1932) 347046

GR

| Centre of Athens Veterinary Institutes |
| --- |
| 25 Neapoleos Street, |
| GR-153 10 Agia Paraskevi Attiki |
| Tel. +30 2106010903 |

Centre of Athens Veterinary Institutes

25 Neapoleos Street,

GR-153 10 Agia Paraskevi Attiki

Tel. +30 2106010903

HU

| Mezőgazdasági Szakigazgatási Hivatal Központ, Állat-egészségügyi Diagnosztikai Igazgatóság |
| --- |
| Central Agricultural Office, Veterinary Diagnostic Directorate |
| Address: 1149 Budapest, Tábornok u. 2. |
| Mailing Address: 1581 Budapest, 146. Pf. 2. |
| Tel. +36 1 460-6300 |
| Fax +36 1 252-5177 |
| E-mail: titkarsag@oai.hu |

Mezőgazdasági Szakigazgatási Hivatal Központ, Állat-egészségügyi Diagnosztikai Igazgatóság

Central Agricultural Office, Veterinary Diagnostic Directorate

Address: 1149 Budapest, Tábornok u. 2.

Mailing Address: 1581 Budapest, 146. Pf. 2.

Tel. +36 1 460-6300

Fax +36 1 252-5177

E-mail: titkarsag@oai.hu

IE

| Virology Division |
| --- |
| Central Veterinary Research Laboratory |
| Department of Agriculture and Food Laboratories |
| Backweston Campus |
| Stacumny Lane |
| Celbridge |
| Co. Kildare |

Virology Division

Central Veterinary Research Laboratory

Department of Agriculture and Food Laboratories

Backweston Campus

Stacumny Lane

Celbridge

Co. Kildare

IT

| Centro di referenza nazionale per la malattia di Aujeszky — |
| --- |
| Pseudorabbia c/o Istituto zooprofilattico sperimentale della Lombardia e dell’Emilia Romagna, |
| Via Bianchi, 9; |
| 25124 Brescia |

Centro di referenza nazionale per la malattia di Aujeszky —

Pseudorabbia c/o Istituto zooprofilattico sperimentale della Lombardia e dell’Emilia Romagna,

Via Bianchi, 9;

25124 Brescia

LT

| National Veterinary Laboratory |
| --- |
| (Nacionalinė veterinarijos laboratorija) |
| J. Kairiūkščio 10 |
| LT-08409 Vilnius |

National Veterinary Laboratory

(Nacionalinė veterinarijos laboratorija)

J. Kairiūkščio 10

LT-08409 Vilnius

LU

| CODA — CERVA — VAR |
| --- |
| Veterinary and Agrochemical Research Centre |
| Groeselenberg 99 |
| B-1180 Brussels |

CODA — CERVA — VAR

Veterinary and Agrochemical Research Centre

Groeselenberg 99

B-1180 Brussels

LV

| Nacionālais diagnostikas centrs |
| --- |
| (National Diagnostic Centre) |
| Lejupes iela 3, Rīga, LV-1076 |
| Tel. +371 7620526 |
| Fax +371 7620434 |
| E-mail: ndc@ndc.gov.lv |

Nacionālais diagnostikas centrs

(National Diagnostic Centre)

Lejupes iela 3, Rīga, LV-1076

Tel. +371 7620526

Fax +371 7620434

E-mail: ndc@ndc.gov.lv

MT

—

NL

| Centraal Instituut voor Dierziekte Controle |
| --- |
| CIDC-Lelystad |
| Hoofdvestiging: Houtribweg 39 |
| Nevenvestiging: Edelhertweg 15 |
| Postbus 2004 |
| 8203 AA Lelystad |

Centraal Instituut voor Dierziekte Controle

CIDC-Lelystad

Hoofdvestiging: Houtribweg 39

Nevenvestiging: Edelhertweg 15

Postbus 2004

8203 AA Lelystad

PL

| Laboratory Departement of Swine Diseases |
| --- |
| Państwowy Instytut Weterynaryjny – Państwowy Instytut |
| Badawczy |
| al. Partyzantów 57, 24-100 Puławy |
| Tel. +48 81 889 30 00 |
| Fax +48 81 886 25 95 |
| E-mail: sekretariat@piwet.pulawy.pl |

Laboratory Departement of Swine Diseases

Państwowy Instytut Weterynaryjny – Państwowy Instytut

Badawczy

al. Partyzantów 57, 24-100 Puławy

Tel. +48 81 889 30 00

Fax +48 81 886 25 95

E-mail: sekretariat@piwet.pulawy.pl

PT

| Laboratório Nacional de Investigação Veterinária (LNIV) |
| --- |
| Estrada de Benfica, 701 |
| P-1549-011 Lisboa |

Laboratório Nacional de Investigação Veterinária (LNIV)

Estrada de Benfica, 701

P-1549-011 Lisboa

SE

| Statens veterinärmedicinska anstalt |
| --- |
| Department of Virology |
| S-751 89 Uppsala |
| Tel. (46-18) 67 40 00 |
| Fax (46-18) 67 44 67 |

Statens veterinärmedicinska anstalt

Department of Virology

S-751 89 Uppsala

Tel. (46-18) 67 40 00

Fax (46-18) 67 44 67

SI

| Univerza v Ljubljani |
| --- |
| Veterinarska fakulteta |
| Nacionalni veterinarski inštitut |
| Gerbičeva 60, |
| SI-1000 Ljubljana |

Univerza v Ljubljani

Veterinarska fakulteta

Nacionalni veterinarski inštitut

Gerbičeva 60,

SI-1000 Ljubljana

SK

| Štátny veterinárny ústav |
| --- |
| Pod dráhami 918 |
| 960 86 Zvolen |
| Slovenska republika |

Štátny veterinárny ústav

Pod dráhami 918

960 86 Zvolen

Slovenska republika

---

ANNEX IV

Criteria on the information to be provided on the occurrence of Aujeszky’s disease (AD) and on plans for the monitoring and eradication of this disease, to be provided in accordance with Article 8 of Council Directive 64/432/EEC

| 1. | Member State: ... |
| --- | --- |

1.

| 2. | Date: ... |
| --- | --- |

2.

| 3. | Reporting period: ... |
| --- | --- |

3.

| 4. | Number of holdings where AD has been detected by means of clinical, serological or virological investigations: ... |
| --- | --- |

4.

| 5. | Information on AD vaccination, serological investigations and categorisation of holdings (please complete the attached table):









  Region | Number of pig holdings | Number of pig holdings under an AD-pogramme (1) | Number of AD not-infected pig holdings
  (with vaccination) (2) | Number of AD free pig holdings
  (without vaccination) (3) |
| --- | --- | --- | --- | --- | --- |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Total | | | | |

5.

Region

Number of pig holdings

Number of pig holdings under an AD-pogramme (1)

Number of AD not-infected pig holdings

(with vaccination) (2)

Number of AD free pig holdings

(without vaccination) (3)

Total

| 6. | Further information on serological monitoring in Artificial Insemination Centres, for export purposes, in the framework of other surveillance schemes, etc.: ...
  ...
  ...
  ... |
| --- | --- |

6.

...

...

...

---

(1)  Programme under the supervision of the competent authority.

(2)  Pig holdings where serological tests for AD have been carried out with negative results in accordance with an official AD programme and where vaccination has been applied during the previous 12 months.

(3)  Pig holdings which fulfil the conditions of Article 1(3).

---

ANNEX V

REPEALED DECISION WITH LIST OF ITS SUCCESSIVE AMENDMENTS

| Commission Decision 2001/618/EC
  (OJ L 215, 9.8.2001, p. 48). | |
| --- | --- |
| Commission Decision 2001/746/EC
  (OJ L 278, 23.10.2001, p. 41). | Only as regards the reference to Decision 2001/618/EC in Article 1 |
| Commission Decision 2001/905/EC
  (OJ L 335, 19.12.2001, p. 22). | Only as regards the reference to Decision 2001/618/EC in Article 2 |
| Commission Decision 2002/270/EC
  (OJ L 93, 10.4.2002, p. 7). | Only Article 3 |
| Commission Decision 2003/130/EC
  (OJ L 52, 27.2.2003, p. 9). | |
| Commission Decision 2003/575/EC
  (OJ L 196, 2.8.2003, p. 41). | |
| Commission Decision 2004/320/EC
  (OJ L 102, 7.4.2004, p. 75). | Only Article 2 and Annex II |
| Commission Decision 2005/768/EC
  (OJ L 290, 4.11.2005, p. 27). | |
| Commission Decision 2006/911/EC
  (OJ L 346, 9.12.2006, p. 41). | Only as regards the reference to Decision 2001/618/EC in Article 1 and point 12 of the Annex |
| Commission Decision 2007/603/EC
  (OJ L 236, 8.9.2007, p. 7). | |
| Commission Decision 2007/729/EC
  (OJ L 294, 13.11.2007, p. 26). | Only as regards the reference to Decision 2001/618/EC in Article 1 and point 10 of the Annex |

Commission Decision 2001/618/EC

(OJ L 215, 9.8.2001, p. 48).

Commission Decision 2001/746/EC

(OJ L 278, 23.10.2001, p. 41).

Only as regards the reference to Decision 2001/618/EC in Article 1

Commission Decision 2001/905/EC

(OJ L 335, 19.12.2001, p. 22).

Only as regards the reference to Decision 2001/618/EC in Article 2

Commission Decision 2002/270/EC

(OJ L 93, 10.4.2002, p. 7).

Only Article 3

Commission Decision 2003/130/EC

(OJ L 52, 27.2.2003, p. 9).

Commission Decision 2003/575/EC

(OJ L 196, 2.8.2003, p. 41).

Commission Decision 2004/320/EC

(OJ L 102, 7.4.2004, p. 75).

Only Article 2 and Annex II

Commission Decision 2005/768/EC

(OJ L 290, 4.11.2005, p. 27).

Commission Decision 2006/911/EC

(OJ L 346, 9.12.2006, p. 41).

Only as regards the reference to Decision 2001/618/EC in Article 1 and point 12 of the Annex

Commission Decision 2007/603/EC

(OJ L 236, 8.9.2007, p. 7).

Commission Decision 2007/729/EC

(OJ L 294, 13.11.2007, p. 26).

Only as regards the reference to Decision 2001/618/EC in Article 1 and point 10 of the Annex

---

ANNEX VI

Correlation table

| Decision 2001/618/EC | This Decision |
| --- | --- |
| Article 1(a) and (b) | Article 1, points 1 and 2 |
| Article 1(c) first to fifth indent | Article 1, point 3(a) to (e) |
| Article 1(d) first to fourth indent | Article 1, point 4(a) to (d) |
| Article 2(a) and (b) | Article 2, points 1 and 2 |
| Article 2(c) first to third indent | Article 2, point 3(a) to (c) |
| Article 3(a) | Article 3, point 1 |
| Article 3(b) first and second indent | Article 3, point 2(a) and (b) |
| Article 3(c) first to sixth indent | Article 3, point 3(a) to (f) |
| Article 4(a) | Article 4, point 1 |
| Article 4(b) first and second indent | Article 4, point 2(a) and (b) |
| Article 4(c) first to fifth indent | Article 4, point 3(a) to (e) |
| Articles 5 to 8 | Articles 5 to 8 |
| Article 9 | — |
| Article 10 | — |
| — | Article 9 |
| Article 11 | Article 10 |
| Annexes I to IV | Annexes I to IV |
| — | Annex V |
| — | Annex VI |

Decision 2001/618/EC

This Decision

Article 1(a) and (b)

Article 1, points 1 and 2

Article 1(c) first to fifth indent

Article 1, point 3(a) to (e)

Article 1(d) first to fourth indent

Article 1, point 4(a) to (d)

Article 2(a) and (b)

Article 2, points 1 and 2

Article 2(c) first to third indent

Article 2, point 3(a) to (c)

Article 3(a)

Article 3, point 1

Article 3(b) first and second indent

Article 3, point 2(a) and (b)

Article 3(c) first to sixth indent

Article 3, point 3(a) to (f)

Article 4(a)

Article 4, point 1

Article 4(b) first and second indent

Article 4, point 2(a) and (b)

Article 4(c) first to fifth indent

Article 4, point 3(a) to (e)

Articles 5 to 8

Articles 5 to 8

Article 9

—

Article 10

—

—

Article 9

Article 11

Article 10

Annexes I to IV

Annexes I to IV

—

Annex V

—

Annex VI

---